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Introduction. Acinetobacter calcoaceticus-baumannii complex (ACB complex) is a leading opportunistic pathogen in intensive
care units (ICUs). Effective control of spread requires understanding of its epidemiological relatedness. This study aims to
determine the genetic relatedness and antibiotic susceptibilities of ACB complex in an ICU in Malaysia.Methodology. Pulsed field
gel electrophoresis (PFGE), E-test, and disk diffusion were used for isolates characterization. Results. During the study period
(December 2011 to June 2012), 1023 patients were admitted to the ICU and 44 ACB complex (blood, 𝑛 = 21, and blind bronchial
aspirates, 𝑛 = 23) were recovered from 38 ICU patients. Six isolates were from non-ICU patients. Of the 44 ICU isolates, 88.6%
exhibited multidrug-resistant (MDR) patterns. There was high degree of resistance, with minimum inhibitory concentration
90
(MIC
90
) of >32 𝜇g/mL for carbapenems and≥256 𝜇g/mL for amikacin, ampicillin/sulbactam, and cefoperazone/sulbactam. Isolates
from the main PFGE cluster were highly resistant. There was evidence of dissemination in non-ICU wards. Conclusion. High
number of clonally relatedMDRACB complex was found.While the ICU is a likely reservoir facilitating transmission, importation
from other wards may be important contributor. Early identification of strain relatedness and implementation of infection control
measures are necessary to prevent further spread.
1. Introduction
The genus Acinetobacter comprises Gram-negative, strictly
aerobic, nonmotile, non-lactose-fermenting, oxidase-nega-
tive, catalase-positive coccobacilli [1]. Members of the Acine-
tobacter calcoaceticus-baumannii complex (ACB complex)
[2, 3] are the predominant Acinetobacter in clinical settings.
Healthcare-associated infections caused by Acinetobacter
baumannii are increasingly seen among immunocompro-
mised populations and frequently cause outbreaks [1–3].
Acinetobacter spp. are among themost common isolates from
intensive care units (ICUs) in most Malaysian hospitals [4].
The challenge ofmanaging infections caused byAcinetobacter
baumannii has been complicated by the emergence
and spread of multidrug-resistance (MDR), with both
endemic and epidemic occurrences [1, 2]. Hospital acquired
pneumonia associated with Acinetobacter spp. in Asian
countries showed very high rate of resistance to imipenem
at 67.3%, with especially high rates in Malaysia (86.7%),
Thailand (81.4%), India (85.7%), and China (58.9%) [5].
In addition to the selection pressure exerted by
widespread antibiotics usage, increased spread of MDR
Acinetobacter baumannii may result from transmissions
of resistant strains via contaminated surfaces, objects, and
colonized healthcare workers [1–3, 6–8]. It is believed
that infection reflects only the tip of an iceberg, with
colonization reflecting the submerged portion [3, 9]. From
an epidemiological perspective, it is useful to determine
the relatedness (clonality) of these organisms, especially in
endemic situations and epidemic outbreaks. If these strains
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are predominantly clonally related, improved compliance
with infection control measures will be necessary [6, 8, 10].
Genotyping of nosocomial A. baumannii is useful to
assess cases of cross-infections or to identify the sources
and modes of spread of the organisms. These genotypic
methods include pulsed field gel electrophoresis (PFGE)
[11], PCR-based fingerprinting, amplified fragment length
polymorphism,multilocus sequence typing (MLST) [12], and
whole genome sequencing [13]. Among these, PFGE is the
most widely used method for strain typing to determine the
genetic relatedness of nosocomial strains [11].
This study attempts to understand the epidemiology of
ACB complex isolated from patients in the ICU by determin-
ing the genetic relatedness and antimicrobial susceptibility
patterns of these isolates.
2. Methodology
2.1. Study Population. This is a retrospective study examining
the molecular epidemiology and antibiotic susceptibilities
of clinical ACB complex conducted at a 989-bed tertiary
care hospital in Johor, Malaysia, and it involved patients
admitted to the ICU. Patients from whom ACB complex was
isolated from blood and blind bronchial aspirates (BBAs)
fromDecember 2011 to June 2012 following admission to one
of the two adult ICUs (West and South) were included in
the study. The West ICU is located on the first floor of the
hospital and has 22 beds: 14 beds with 1 : 1 nurse-to-patient
ratio and 8 beds with 1 : 2 ratio. The South ICU is located on
the second floor of the hospital and has 7 beds, all with 1 : 1
nurse-to-patient ratio. The infection control practices follow
the consensus statement of infection controlmeasures in ICU
by the Intensive Care Section of the Malaysian Society of
Anaesthesiologists (2009).
A total of 44 clinical isolates of ACB complex were
isolated from ICU during the study period. In addition, 6
non-ICU isolates (blood, 𝑛 = 4, and BBA, 𝑛 = 2) were
available and were included in the PFGE typing to determine
whether they were clonally related to the ICU strains.
2.2. Clinical Data. Clinical data was extracted from the
case report forms of the ICU patients with ACB complex
cultured from blood and BBA. The following data were
obtained from these patients: demographic characteristics,
possible predisposing factors, prior and current antibiotic
use, duration of ICU stay (Figure 3), clinical outcome, and
whether the isolated organism was regarded as causing an
infection or colonization. Clinical data was not retrieved for
the 6 non-ICU patients.
ACB complex strains were regarded as colonizers based
on the clinical judgement (clinical signs, laboratory param-
eters, and chest radiology findings) of the attending doctor.
Invasive device as a risk factor was defined as having a
device or invasive procedure for at least 48 hours within the
2 weeks preceding the date of the positive cultures. Prior
antibiotic exposure was defined as the use of a systemic
antibiotic agent for at least 72 hours within the 2 weeks
preceding the date of the positive culture.Multidrug-resistant
(MDR) ACB complex was defined as an isolate that was not
susceptible (intermediately resistant or resistant) to three or
more antimicrobials classes [14].
2.3. Bacterial Identification and Antimicrobial Susceptibility
Testing. All blood cultures were processed by the clinical
microbiology laboratory using the BACTEC 9240 system
(Becton Dickinson and Company, Franklin Lakes, NJ, USA).
ACB complex was identified by standard microbiological
techniques (nonmotile, strictly aerobic, Gram-negative coc-
cobacilli, catalase-positive and oxidase-negative, and inability
to ferment glucose) and API 20 NE (bioMe´rieux, Marcy-
l’E´toile, France).
Antibiotic susceptibility was performed using a panel
of 11 different antimicrobial agents and was determined
by means of Kirby-Bauer disk diffusion method using the
guidelines provided by Clinical Laboratory Standard Insti-
tute (CLSI, 2012) [15]. The ACB complex isolates were
tested against ampicillin/sulbactam (10/10 𝜇g), imipenem
(10 𝜇g), meropenem (10 𝜇g), gentamicin (10 𝜇g), amikacin
(30 𝜇g), ceftazidime (30 𝜇g), cefepime (30 𝜇g), piperacillin/
tazobactam (100/10 𝜇g), cefoperazone/sulbactam (30/75𝜇g),
ciprofloxacin (5 𝜇g), and colistin (10 𝜇g) (Oxoid, Ltd., Bas-
ingstoke, Hampshire, England).
The E-test was used to determine the minimal inhibitory
concentrations (MIC) of ampicillin/sulbactam, doripenem,
meropenem, amikacin, cefoperazone/sulbactam, and colistin
(AB BIODISK, Solna, Sweden) against ACB complex based
on CLSI guidelines [15]. Since there are no CLSI interpre-
tation criteria relevant to ACB complex for cefoperazone/
sulbactam, the susceptibility breakpoints for these antibiotics
were based on the MIC interpretive standards of CLSI for
Enterobacteriaceae [15]. Escherichia coli ATCC 35218 and
Pseudomonas aeruginosa ATCC 27853 were used as quality
control strains.
2.4. Molecular Typing Using PFGE. Molecular subtyping of
the 50 ACB complex isolates was carried out using pulsed
field gel electrophoresis (PFGE), as previously described [16].
Briefly, chromosomal DNA of these ACB complex isolates
was prepared in agarose gel blocks, followed by digestion
using ApaI restriction enzyme (Promega, Madison, WI,
USA). Then, restricted DNA fragments were separated using
CHEFMapper (Bio-Rad, Hercules, CA, USA). Gels were run
at 14∘C in 0.5x TBE buffer for 24 hours, with pulse time
of 2–40 seconds. The XbaI-digested Salmonella enterica ser.
BraenderupH9812 was used as themolecularmarker in these
runs. Cluster analysis of the PFGE profiles was based on
the Dice coefficient of similarity analyzed by BioNumerics
6.0 software (Applied Maths, Kortrijk, Belgium) using the
Unweighted Pair Group Method with Arithmetic Averages
(UPGMA) algorithm at 1.5% band position tolerance. Only
DNA bands within the molecular marker (20.5 kb–1135 kb)
were scored.
2.5. Ethical Approval. The study was approved by the
Malaysian Ministry of Health Medical Research Ethics Com-
mittee (NMRR-13-288-14809). Informed consent was not
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Table 1: Clinical characteristics of 35 patients with ACB Complex.
Characteristics 𝑁 (%)/median (range)
Age (years)∗ 46 (14–73)
Length of ICU stay (days)∗ 13 (3–46)
Gender (male) 23 (65.7)
Bacteraemia 17 (48.6)
APACHE score∗ 22 (14–44)
Diabetes mellitus 9 (25.7)
Hypertension 8 (22.9)
Malignancy 3 (8.6)
Renal disease 5 (14.3)
Cardiac disorder 3 (8.6)
Respiratory disorder 3 (8.6)
Neutropenia 2 (5.7)
Polytrauma 8 (22.9)
Respiratory disorder 3 (8.6)
Prior antibiotic therapy 33 (94.3)
ES cephalosporins 13 (37.1)
Broad-spectrum penicillin 23 (65.7)
Quinolones 1 (2.9)
Carbapenem 16 (45.7)
Aminoglycosides 3 (8.6)
Metronidazole 4 (11.4)
Macrolide 4 (11.4)
Cotrimoxazole 2 (5.7)
Number of prescribed antibiotics∗ 2 (0–6)
Number of invasive procedures/devices∗ 3 (2–5)
Central venous catheter 35 (100)
Endotracheal tube 35 (100)
Urinary catheter 28 (80)
Dialysis catheter 15 (42.9)
Drainage 3 (8.6)
Prior surgical procedure 3 (8.6)
ICU outcome (died) 17 (48.6)
All characteristics are expressed as number (%), except ∗ which is expressed
as median (range).
obtained from the patients, as this was a retrospective study
and the data was collected after patients had been discharged.
3. Results
3.1. Clinical Characteristics. During the 7-month period of
the study, 1023 patients were admitted to the two adult ICUs
and a total of 44 ACB complex positive cultures (blood,
𝑛 = 21, and BBA, 𝑛 = 23) from 38 ICU patients were
identified. The clinical data from 35 patients was available
for analysis (Table 1). The median patient age was 46 years
(range: 14 to 73 years) and 65.7% of patients were males. All
patients were ventilated and had central venous catheters.
The median number of invasive devices was 3 (ranging from
2 to 5). Almost all patients (94.3%) had received antibiotics
within 2 weeks of the positive ACB complex culture, the
most common being broad-spectrum penicillins (65.7%),
carbapenems (45.7%), and broad-spectrum cephalosporins
(37.1%). Twenty-two (63%) patients had received ≤2 antibi-
otics and 11 (31.4%) had received ≥3 antibiotics. However,
the number of antibiotics prior to culture positivity was not
significantly higher among patients with MDRACB complex
(𝑃 = 0.565). The most common diagnoses upon admission
to the ICU were motor vehicle accident with polytrauma
(𝑛 = 8 patients). The mean (±SD) Acute Physiology and
Chronic Health Evaluation (APACHE) II score was 23.2
(±7.0), with no significant difference between the MDR
and non-MDR groups (𝑃 = 0.781). The most frequent
comorbidities in this study were diabetes mellitus (25.7%)
and hypertension (22.9%).The median time that had elapsed
between admission and isolation of ACB complex was 5
days (range: 0 to 38 days); in 4 patients, ACB complex was
recovered within the first 48 hours after admission. The
median length of ICU stay was 13 days (range: 3 to 46 days).
While all the bacteraemic cultures were regarded as clinically
significant, all the BBA isolates were deemed to be colonizers.
Overall mortality was 57% (20 out of 35 patients); 17 patients
died while being in ICU and 3 died after being transferred
out of ICU. While mortality was associated with underlying
disease in 16 patients, in 4 patients it was believed to be
directly related to ACB complex sepsis. These 4 patients were
treated with polymyxin B and were severely compromised
because of the underlying condition; first patient had severe
burns, 2 patients had multiple injuries sustained in a motor
vehicle accident, and the fourth patient had cancer of ovary.
Despite the administration of appropriate antibiotic therapy,
these patients succumbed to their illness.
Overall, polymyxin B was used to treat ACB complex
infections in 11 patients and cefoperazone/sulbactam was
used in 2 patients. In 18 patients, antibiotics were not admin-
istered as these BBA cultures were regarded as clinically
nonsignificant, whereas in 4 patients antibiotics were not
commenced as laboratory results were available only after the
patients had died.
3.2. Antimicrobial Susceptibility. The antibiotic susceptibility
pattern (disk diffusion) of the 44ACB complex isolates as pre-
sented in Table 2 showed that majority (>80%) of the isolates
were nonsusceptible (resistant and intermediately suscepti-
ble) to carbapenems, ciprofloxacin, piperacillin/tazobactam,
ceftazidime, cefepime, cefoperazone/sulbactam, and ampi-
cillin/sulbactam. Slightly better results were demonstrated
with the aminoglycosides (nonsusceptibility rates of 79.5% for
gentamicin and 72.7% for amikacin). Of the 44 ICU isolates,
88.6% exhibited MDR patterns. All strains were susceptible
to colistin. Results of the MIC of selected antibiotics are
shown in Table 3. MIC
50
and MIC
90
for both doripenem and
meropenemwere 32𝜇g/mL or higher, suggesting high degree
of resistance to carbapenems in this collection. Most isolates
were highly resistant to amikacin with MIC
50
and MIC
90
of >256𝜇g/mL. Twenty-two (50%) isolates were resistant
to cefoperazone/sulbactam with 14 (31.8%) demonstrating
intermediate susceptibility. Ampicillin/sulbactam, another
commonly used antibiotic, demonstrated higher resistance
compared to cefoperazone/sulbactam: 72.7% (resistant) and
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Table 2: Antimicrobial susceptibility (disc diffusion) of 44 ACB
complex isolates recovered from 38 ICU patients.
Antibiotics Nonsusceptible
(intermediate and resistant) (%)
GEN 35 (79.5)
AKN 32 (72.7)
IMI 39 (88.6)
MER 39 (88.6)
CIP 37 (84.1)
PZ 39 (88.6)
CAZ 38 (86.4)
FEP 39 (88.6)
AMS 37 (84.1)
CPS 37 (84.1)
COL 0
GEN, gentamicin; AKN, amikacin; IMI, imipenem; MER, meropenem; CIP,
ciprofloxacin; PZ, piperacillin/tazobactam;CAZ, ceftazidime; FEP, cefepime;
AMS, ampicillin/sulbactam; CPS, cefoperazone/sulbactam; COL, colistin.
Antimicrobial categories: aminoglycosides (gentamicin and amikacin);
antipseudomonal carbapenems (imipenem and meropenem); antipseudo-
monal fluoroquinolones (ciprofloxacin); antipseudomonal penicillin + 𝛽-
lactamase inhibitors (piperacillin/tazobactam); extended-spectrumcephalo-
sporins (ceftazidime and cefepime); penicillins+ 𝛽-lactamase inhibitors
(ampicillin/sulbactam), cephalosporin+ 𝛽-lactamase inhibitors (cefopera-
zone/sulbactam); polymyxin (colistin).
MDR: nonsusceptible to ≥1 agent in ≥3 antimicrobial categories.
13.6% (intermediate susceptibility). Extremely high MIC
value of 256𝜇g/mL was required to inhibit 90% of ACB com-
plex with ampicillin/sulbactam, cefoperazone/sulbactam,
and amikacin. The BBA isolates had higher MIC
90
for ampi-
cillin/sulbactam and cefoperazone/sulbactam compared to
blood isolates, although not significantly different. The MIC
distribution of colistin was as follows: 0.125𝜇g/mL (𝑛 = 1),
0.190 𝜇g/mL (𝑛 = 3), 0.250𝜇g/mL (𝑛 = 23), 0.380 𝜇g/mL
(𝑛 = 7), 0.5 𝜇g/mL (𝑛 = 9), and 1 𝜇g/mL (𝑛 = 1). The cut-off
MIC values for colistin are as follows: sensitive, ≤ 2𝜇g/mL,
intermediate, 4 𝜇g/mL, and resistant, ≥ 8𝜇g/mL.
3.3. Genetic Diversity. PFGE separation of ApaI-digested
chromosomal DNA of 50 isolates (ICU = 44 and non-ICU =
6) generated 25 distinct, reproducible patterns (pulsotypes)
(Figure 1). A dendrogram based on all the pulsotypes was
generated (Figure 2). On the basis of 85% similarity, four
clusters, G1 to G4, were observed (Figure 2). The major
cluster, G1, consisted of 35 isolates with closely related
pulsotypes (less than 4-band difference). A predominant
endemic pulsotype was shared among 18 ICU and three
non-ICU isolates. Twenty isolates (blood and BBA samples)
isolated throughout the study period from ICU and non-ICU
wards were indistinguishable, indicating their endemicity.
The G1 cluster consisted of isolates from both ICUs (West
and South) and included 4 patients whose cultures (blood = 2
and BBA = 2) were taken within 48 hours of ICU admission.
This isolate was also recovered from 3 patients who were not
admitted to either of the 2 ICUs. Except for 5 isolates, cluster
G1 contained isolates that were highly resistant to carbapen-
ems (MIC ≥ 32 𝜇g/mL) and amikacin (MIC ≥ 256𝜇g/mL)
(Figure 2). Similarly, majority of the isolates were resistant to
ampicillin/sulbactam and cefoperazone/sulbactam, although
the MICs were more variable.
In contrast to cluster G1 isolates, which were recovered
from West and South ICUs and the non-ICU wards, the 6
isolates within cluster G2 were recovered exclusively from
West ICU. Unlike cluster G1, these isolates were mostly
susceptible to amikacin (except strain JBAC30). Within this
cluster, two isolates (JBAC11 and JBAC13) isolated from
same patient from different body sites had identical unique
pulsotype.
Cluster G3 consisted of two isolates with a unique pulso-
type recovered from West ICU. These blood isolates which
were recovered 15 days apart from the same patient were
identical but distinctly different from the other A. baumannii
(with more than 5-6-band difference), indicating persistent
infection in the same individual.
Cluster G4 comprised non-ICU isolates recovered from
blood and they were more variable, indicating the discrimi-
natory power of PFGE. Except for JBAC02, the other isolates
(JBAC23) in clusterG4were sensitive to the tested antibiotics.
By and large, vast majority (70%) of the MDR isolates
belonged to G1 cluster and 14.3% of them belonged to G2
cluster. No MDR isolates were found in G3 and G4 clusters.
4. Discussion
In this study, PFGE was proved to be a discriminative
genotyping tool. We found evidence of a dominant genotype
(cluster G1) of MDR ACB complex in vast majority (74%)
of the isolates. These isolates were recovered from patients
cared for in both ICUs (West and South) throughout the 7-
month period of the study, raising serious concerns about
the persistence and resilience of this epidemic strain. The
high genetic relatedness of these isolates suggests cross-
transmission within the ICU setting. Four isolates belonging
to cluster G1 were identified within 48 hours of ICU admis-
sion from non-ICU wards, supporting the probable rate of
transmission from the non-ICUwards.However, the 48-hour
criterion for ICU acquisition should be interpretedwith some
caution, as epidemic strains have been acquired within 48
hours of ICU admission [17].
There was also evidence of dissemination of this domi-
nant genotype in the non-ICU wards, as 3 out of 6 randomly
collected non-ICU blood isolates showed similar genotype.
Based on this, we can assume that this particular genotype
of ACB complex might not be confined to the ICU wards
alone butmay actually be found in otherwards in the hospital.
Nevertheless, although transfer from non-ICU wards was a
likely contributory factor, the ICU itself is a probable reser-
voir facilitating transmission as the resistant clone seemed
endemic and persistent in the ICU. In a study conducted in
another tertiary teaching hospital inMalaysia, Kong et al. [16]
demonstrated that this organism had established endemicity
in that hospital as isolates from the environment and hands
of healthcare workers and patients were indistinguishable.
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Table 3: MIC (𝜇g/mL) for 44 ACB complex isolates recovered from 38 ICU patients.
Antibiotic 𝑆 (%) 𝐼 (%) 𝑅 (%) MIC50 MIC90
All B BBA All B BBA
AMS 6 (13.6) 6 (13.6) 32 (72.7) 64 64 64 256 128 >256
DOR 6 (13.6) 0 (0) 38 (86.4) >32 >32 >32 >32 >32 >32
MER 6 (13.6) 0 (0) 38 (86.4) >32 >32 >32 >32 >32 >32
AKN 14 (31.8) 0 (0) 30 (68.2) >256 >256 >256 >256 >256 >256
CPS 8 (18.2) 14 (31.8) 22 (50) 48 48 64 256 128 256
COL 44 (100) 0 (0) 0 (0) 0.25 0.38 0.25 0.5 0.5 0.5
B, blood; BBA, bronchoscopic aspirate; AMS, ampicillin/sulbactam; DOR, doripenem; MER, meropenem; AKN, amikacin; CPS, cefoperazone/sulbactam;
COL, colistin.
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Figure 1: Pulsotypes of 50 clinical ACB complex isolates from a tertiary hospital in Malaysia. Lane M represents Salmonella ser. Braenderup
H9812 as the marker. Lanes 1–50 represent clinical isolates JBAC01-JBAC50.
The striking similarity among the isolates suggests cross-
transmission which may occur by direct contact by infected
or colonized person or indirectly through environmental
contamination, medical devices, or healthcare workers [1–
3, 6–8]. In the present study, the role of environmental source
could not be adequately investigated partly because we did
not have a complete collection of the isolates. However, A.
baumannii is able to survive for long periods of time on
dry surfaces and this tolerability to desiccation contributes
to its persistence in hospital environments and transmis-
sion through fomites [1, 10]. Wilks et al. [8] reported a
recent outbreak of MDR Acinetobacter infection with envi-
ronmental contamination found on curtains, laryngoscope
blades, patient lifting equipment, door handles, mops, and
keyboards.
Outbreaks caused by MDR ACB complex have been
reported in several ICUs worldwide [6–8]. Analysis of resis-
tance determinants and genetic relatedness demonstrated
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Figure 2: Dendrogramof the PFGEprofiles ofApaI-digested 50ACB complex isolates usingUnweighted Pair GroupMethodwithArithmetic
Averages (UPGMA).The dotted vertical line indicates the cut-off point of 85% similarity.The different clusters at 85% similarity are arbitrarily
designated G1–G4, whereby G1 is the largest group representing the most prevalent pulsotypes and its variants among the isolates.
that widespread dissemination of a highly resistant dominant
G1 cluster had contributed to the high prevalence of MDR
ACB complex in the ICU (88.6%). The second most preva-
lent cluster (cluster G2) comprised 12% of the isolates and
prevailed primarily in the West ICU. The isolates within
this cluster were also highly resistant, except that unlike
the isolates in cluster G1 they remain sensitive to amikacin.
Two other minor clusters (G3 and G4) comprising mainly
sensitive isolates also coexisted during the study period. This
concurred with another study by Lean et al. [11], whereby
multiple subtypes (pulsotypes < 4-band difference) of
A. baumanniiwere shown to exist in another tertiary hospital
in Malaysia.
Overall, PFGE revealed that the isolates were genetically
related, which is typical of outbreak episodes. Nevertheless,
PFGE was discriminative enough to differentiate unrelated
isolates as seen in 3 out of the 6 non-ICU isolates which
had unique profiles (cluster G4) and 2 other isolates taken
from the same patient 15 days apart within G3 cluster.
However, because of the endemicity of the predominant
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Figure 3: Timeline for ICU stay for patients infected/colonized with
ACB complex, December, 2011, to June, 2012.
ACB complex cluster, more discriminative methods, other
than PFGE, such as whole genome sequencing (WGS) may
be needed to pinpoint the source of transmission routes of
very closely related ICU strains. WGS provides the ultimate
strain differentiation and has been successfully applied to
investigate nosocomial outbreaks caused by A. baumannii
[13], MRSA [18, 19], and Klebsiella pneumoniae [20].
Concurring with other studies [9, 21], the highly
immunocompromised nature of our patients predisposed
them to serious ACB complex infection as evidenced by 21
episodes of bacteraemia. Although the 23 BBA cultures were
deemed to be colonizers clinically, identification of colonizers
becomes equally important as colonization may serve as an
exogenous source of infection and colonization for other
patients and may be a risk factor for subsequent endogenous
infections [2, 22]. Since majority of the isolates were clonally
related, emphasis should be placed on preventing acquisition
and transmission of this infection [6, 10]. Once endemic
in a healthcare setting, A. baumannii or ACB complex can
be extremely challenging to eliminate. Numerous outbreaks
of MDR A. baumannii have been documented in Asian
countries. An A. baumannii outbreak in an ICU in Taiwan
was interrupted through the institution of cohort nursing of
patients, improved hand hygiene, and effective environmen-
tal and equipment decontamination [22]. Active surveillance
and environmental cleaning resulted in sustained reduction
of MDR A. baumannii colonization and infection rates and
reduced the cost of antibiotics usage and hospitalization
among ICU patients in Thailand [9]. Another such outbreak
in Singapore was ceased only after the ICU was closed for
complete cleaning, although initial control measures which
included screening of all patients and immediate isolation
and cohorting of patients with contact precautions helped in
containing the outbreak [23].
5. Conclusions
PFGE analysis revealed that the ACB complex isolated from
the ICU patients belongs mainly to one major cluster. While
the ICU itself is a likely reservoir facilitating transmission,
importation of strains from other wards of the hospital may
be an important contributory factor. However, regardless of
the original source of the outbreak strain and whether it
was subsequently transmitted from human or environmental
source, early identification and close scrutiny together with
prompt implementation of multidisciplinary infection con-
trol interventions are required to prevent further spread in
the ICU.
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